Nephron Experimental Nephrology

Original Paper

Renal and Urinary Glycosaminoglycans in an Experimental Model of Chronic Renal Failure in Rats

Michelacci Y.M.a · Cadaval R.A.M.b · Rovigatti R.M.a · Kohlman O.b

Author affiliations

aDisciplina de Biologia Molecular, Departamento de Bioquímica, and bDisciplina de Nefrologia, Departamento de Medicina, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil

Related Articles for ""

Exp Nephrol 2001;9:40–48

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: October 06, 2000
Issue release date: October 2000

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 4


eISSN: 1660-2129 (Online)

For additional information: https://www.karger.com/NEE

Abstract

The present paper reports the glomerular and renal individual glycosaminoglycan levels in an experimental model of chronic renal failure (CRF) that was induced in Wistar rats by five-sixths mass ablation. Glycemia, body weight, blood systolic pressure and urinary excretions of creatinine, albumin and glycosaminoglycans were measured for 12 weeks. At the end of the experiment, the weight and the glycosaminoglycan composition of the kidneys were determined. In control rats, heparan sulfate was the main glycosaminoglycan found both in whole kidney and isolated glomeruli, with trace amounts of dermatan sulfate. Isolated glomeruli presented higher heparan sulfate concentrations than whole kidney (expressed as mg/g dry weight). In CRF rats, albuminuria appeared from the 2 week on, and dermatan sulfate and chondroitin sulfate contents of the kidney increased, whereas heparan sulfate levels remained unaltered. Changes in urine glycosaminoglycans (heparan sulfate, chondroitin sulfate and dermatan sulfate) were not statistically significant. The increase in glomerular dermatan sulfate and chondroitin sulfate observed in this experimental model could be related to the mechanisms involved in the glomerulosclerosis and proteinuria that occur in CRF.

© 2000 S. Karger AG, Basel




Related Articles:


References

  1. Vogel KG: Glycosaminoglycans and proteoglycans; in Yurchenco PD, Birk DE, Mechan EP (eds): Extracellular Matrix Assembly and Structure: Biology of Extracellular Matrix. New York, Academic Press, 1994, pp 243–279.
  2. Iozzo RV: Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 1998;67:609–652.
  3. Dietrich CP, Sampaio LO, Toledo OMS, Cássaro CMF: Cell recognition and adhesiveness: A possible role for the sulfated mucopolysaccharides. Biochem Biophys Res Commun 1977;75:329–336.
    External Resources
  4. Dietrich CP: A model for cell-cell recognition and control of cell growth mediated by sulfated glycosaminoglycans. Braz J Med Biol Res 1984;17:5–15.
    External Resources
  5. Dietrich CP, Armelin HA, Nogueira YL, Nader HB, Michelacci YM: Turnover, change of composition with rate of cell growth and effect of phenylxyloside on synthesis and structure of cell surface sulfated glycosaminoglycans of normal and transformed cells. Biochim Biophys Acta 1982;717:387–397.
    External Resources
  6. Ruoslahti E: Proteoglycans in cell regulation. J Biol Chem 1989;264:13369–13372.
  7. Dietrich CP, Sampaio LO, Toledo OMS: Characteristic distribution of sulfated mucopolysaccharides in different tissues and in their respective mitochondria. Biochem Biophys Res Commun 1976:71:1–10.
    External Resources
  8. Cássaro CMF, Dietrich CP: Distribution of sulfated mucopolysaccharides in invertebrates. J Biol Chem 1977;252:2254–2261.
    External Resources
  9. Misevic GN, Burger MM: Involvement of highly polyvalent glycan in the cell-binding of the aggregation factor from the marine sponge Microciona prolifera. J Cell Biochem 1990;43:307–314.
    External Resources
  10. Couchman JR, Beavan LA, McCarthy KJ: Glomerular matrix: Synthesis, turnover and role in mesangial expansion. Kidney Int 1994;45:328–335.
  11. Kanwar YS, Jakubowski ML, Rosenzweig LJ: Distribution of sulfated glycosaminoglycans in the glomerular basement membrane and mesangial matrix. Eur J Cell Biol 1983;31:290–295.
    External Resources
  12. Farquhar MG: The glomerular basement membrane: A selective macromolecular filter; in Hay ED (ed): Cell Biology of Extracellular Matrix, ed 2. New York, Plenum Press, 1991, pp 365–418.
  13. Stow JL, Farquhar MG: Distinctive populations of basement membrane and cell membrane heparan sulfate proteoglycans are produced by cultured cell lines. J Cell Biol 1987;105:529–539.
    External Resources
  14. Klein DJ, Brown DM, Oegema TR Jr: Partial characterization of heparan and dermatan sulfate proteoglycans synthesized by normal rat glomeruli. J Biol Chem 1986;261:16636–16652.
    External Resources
  15. Reubsaet FAG, Langevelt JPM, Veerkamp JH: Glycosaminoglycan content of glomerular and tubular basement membranes of various mammalian species. Biochim Biophys Acta 1985;838:144–150.
    External Resources
  16. Pyke C, Kristensen P, Ostergaard PB, Oturai PS, Romer J: Proteoglycan expression in the normal rat kidney. Nephron 1997;77:461–470.
  17. Kanwar YS, Linker A, Farquhar MG: Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980;86:688–693.
    External Resources
  18. Mauer SN, Lane P, Hattori M, Fioretto P, Steffes MW: Renal structure and function in insulin-dependent diabetes mellitus and type I membranoproliferative glomerulonephritis in humans. J Am Soc Nephrol 1992;2(suppl):181–184.
  19. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324–F337.
    External Resources
  20. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas AM: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 1997:99:2950–2960.
  21. Cifonelli JA, Dorfman A: Properties of heparin monosulfate (heparitin sulfate). J Biol Chem 1960;235:3283–3291.
  22. Nader HB, Porcionatto MA, Tersariol ILS, Pinhal MAS, Oliveira FW, Moraes CT, Dietrich CP: Purification and substrate specificity of heparitinase I and heparitinase II from Flavobacterium heparinum. J Biol Chem 1990;265:16807–16813.
    External Resources
  23. Michelacci YM, Horton DSPQ, Población CA: Isolation and characterization of an induced chondroitinase ABC from Flavobacterium heparinum. Biochim Biophys Acta 1987;923:291–301.
    External Resources
  24. Mancini G, Carbonara AO, Heremans JF: Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235–254.
  25. Savin VJ, Terreros DA: Filtration in single isolated mammalian glomeruli. Kidney Int 1981;20:188–197.
  26. Toma S, DiFerrante DT, Tenni R, DiFerrante N, Michelacci YM: Preparation from keratan sulfate of substrates for the measurement of 2-acetamido–2-deoxy-D-glucose-6-sulfate sulfatase and (1→3)-N-acetyl-β-D-glucosaminidase. Carbohydr Res 1981;88:93–105.
  27. Dietrich CP, McDuffie N, Sampaio LO: Identification of acidic mucopolysaccharides by agarose gel electrophoresis. J Chromatogr 1977;130:299–304.
  28. Hadad SJ, Michelacci YM, Schor N: Proteoglycans and glycosaminoglycans synthesized in vitro by mesangial cells from normal and diabetic rats. Biochim Biophys Acta 1996:1290:18–28.
  29. Dietrich CP, Nader HB: Fractionation and properties of four heparitin sulfates from beef lung tissue: Isolation and partial characterization of a homogeneous species of heparitin sulfate. Biochim Biophys Acta 1974;343:34–44.
    External Resources
  30. Petricevich VL, Michelacci YM: Proteoglycans synthesized in vitro by nude and normal mouse peritoneal macrophages. Biochim Biophys Acta 1990;1053:135–143.
    External Resources
  31. Hilborn JC, Anastassiadis PA: Estimation of the molecular weights of acidic mucopolysaccharides by polyacrylamide gel electrophoresis. Anal Biochem 1971;39:88–92.
    External Resources
  32. Población CA, Michelacci YM: Structural differences of dermatan sulfates from different origins. Carbohydr Res 1986;147:87–100.
  33. Kobayashi S, Oguri K, Kobayashi K, Okayama M: Isolation and characterization of proteoheparan sulfate synthesized in vitro by rat glomeruli. J Biol Chem 1983;258:12055–12057.
  34. Stow JL, Glasgow EF, Handley CJ, Hascall VC: Biosynthesis of proteoglycans by isolated rabbit glomeruli. Arch Biochem Biophys 1983;225:950–957.
    External Resources
  35. van den Heuvel LPWJ, Veerkamp JH, Monnens LAH, Schroeder CH: Heparan sulfate proteoglycan from human and equine glomeruli and tubules. Int J Biochem 1988;20:1391–1400.
  36. Kato M, Koike Y, Suzuki S, Kimata K: Basement membrane proteoglycan in various tissues: Characterization using monoclonal antibodies to Wengelbreth-Holm-Swarm mouse tumor low density heparan sulfate proteoglycan. J Cell Biol 1988;106:2203–2210.
  37. van den Heuvel LPWJ, van den Born J, van den Velden TJAM, Veerkamp JH, Monnens LAH, Schroeder CH, Berden JHM: Isolation and partial characterization of heparan sulfate proteoglycan from the human glomerular basement membrane. Biochem J 1989;264:457–465.
  38. Davies M, Thomas GJ, Shewring LD, Mason RM: Mesangial cell proteoglycans: Synthesis and metabolism. J Am Soc Nephrol 1992;2(suppl): 88–94.
  39. Schaefer L, Hausser H, Altenburger M, Ugorcakova J, August C, Fisher LW, Schaefer RM, Kresse H: Decorin, biglycan and their endocytosis receptor in rat renal cortex. Kidney Int 1998;54:1529–1541.
  40. Mogyorosi A, Ziyadeh FN: What is the role of decorin in diabetic kidney disease? Nephrol Dial Transplant 1999;14:1078–1081.
  41. Vleming LJ, Baelde JJ, Westendorp RG, Daha MR, van Es LA, Bruijn JA: Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 1995;44:211–219.
  42. Cadaval RA, Kohlman O, Michelacci YM: Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology, in press.
  43. Sarica K, Türkölmez K, Soygür T, Özer G, Yaman MO, Baltaci S, Bedük Y, Müftüoglu YZ: Evaluation of urinary glycosaminoglycan excretion in patients with renal cell carcinoma. Eur Urol 1997;31:54–57.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: October 06, 2000
Issue release date: October 2000

Number of Print Pages: 9
Number of Figures: 6
Number of Tables: 4


eISSN: 1660-2129 (Online)

For additional information: https://www.karger.com/NEE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP